Susan Lee
Psychiatry · New York, NYNPI 1932273596
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 105 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 29.4% of the total. Reporting peaked in 2019 at $4,530 and has fallen 94.0% since, to $272 in 2025. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 105 payments — averaging $59.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$881
- Alkermes, Inc.$625
- Takeda Pharmaceuticals U.S.A., Inc.$581
- Sunovion Pharmaceuticals Inc.$494
- Teva Pharmaceuticals USA, Inc.$382
- plus $1K from 11 others
What the payments were for
- Food & beverage$6,292100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 28 | $1,851 |
| Otsuka America Pharmaceutical, Inc. | 8 | $881 |
| Alkermes, Inc. | 5 | $625 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $581 |
| Sunovion Pharmaceuticals Inc. | 6 | $494 |
| Teva Pharmaceuticals USA, Inc. | 3 | $382 |
| Lundbeck LLC | 22 | $335 |
| Neurocrine Biosciences, Inc. | 2 | $298 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $242 |
| Johnson & Johnson | 3 | $170 |
| Madrigal Pharmaceuticals | 1 | $150 |
| Grifols USA, LLC | 1 | $125 |
| Supernus Pharmaceuticals, Inc. | 5 | $79 |
| Eisai Inc. | 1 | $25 |
| Gilead | 1 | $23 |
| Bausch Health US, LLC | 1 | $17 |
| Shire North American Group Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$2,499
- VRAYLAR$1,636
- ARISTADA INITIO$625
- ABILIFY MAINTENA$487
- LATUDA$470
- REXULTI$375
- INGREZZA$298
- AUSTEDO$260
- TRINTELLIX$245
- REZDIFFRA$150
- HyperRAB$125
- SPRAVATO$124
- UZEDY$122
How this compares
$6,292 in reported general payments places this provider in the 90th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in New York
- Manish ZinzuvadiaNew York$1.3M
- Jianping ChenNew York$1.2M
- Ulla Kristina LaaksoNew York$890K
- Kerry SulkowiczNew York$435K
- Ralph AquilaNew York$143K
- Daniel KarlinNew York$101K
- David StraussNew York$95K
- Anissa Abi-DarghamNew York$94K
- Robin McGarryNew York$69K
- Nicole AllenNew York$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.